VetClick
Menu Menu
Login

VetClick

/ News
Tuesday, 30th April 2024 | 4,321 veterinary jobs online | 120 people actively seeking work | 5,486 practices registered

Veterinary Industry News

Send us your news

Boehringer Ingelheim Vetmedica Launches Prascend®

14 years ago
9768 views

Posted
8th October, 2010 10h36


Boehringer Ingelheim Vetmedica has launched Prascend®, the first licensed product for the treatment of Pituitary Pars Intermedia Dysfunction (PPID) in horses, commonly known as Equine Cushings Disease. Pack blister tablets Prascend contains pergolide mesylate, and is supplied in 60 and 160 tablet packs of 1mg tablets. Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica, comments: “Many horses and ponies with Cushings Disease benefit from treatment with pergolide, however, with less than 200 people still being treated with pergolide in the UK, many vets and horse owners have expressed concern that they will not be able access treatment in the future. “We have invested in dedicated veterinary manufacturing of this product, and can assure our customers that the future supply of Prascend is guaranteed irrespective of any changes of in the human generic market.” For further information, visit www.prascend.co.uk or call 01344 746959.

More from


You might be interested in...